Conditions

GLP-1 and Sleep Apnea: Can Zepbound Treat OSA?

GLP-1 Companion · 8 min read

Obstructive sleep apnea (OSA) affects an estimated 30 million Americans, yet it has historically been managed almost exclusively with devices — primarily CPAP machines. For decades, no medication had ever been approved specifically to treat OSA. That changed in December 2024, when the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, marking a historic first in sleep medicine.

The SURMOUNT-OSA Trial: What It Found

The approval was based on the SURMOUNT-OSA program, which consisted of two parallel Phase 3 randomized controlled trials involving over 460 participants with moderate-to-severe OSA and obesity. One trial included patients who were not using PAP (positive airway pressure) therapy; the other included patients who continued their PAP therapy alongside the study medication. Both trials ran for approximately 52 weeks.

The primary outcome measure was change in the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep. A normal AHI is under 5. Moderate OSA is defined as AHI 15–30 and severe OSA as AHI above 30.

• In the non-PAP trial, tirzepatide reduced AHI by 55% from baseline versus a 5% reduction with placebo.
• In the PAP-use trial, tirzepatide reduced AHI by 63% from baseline versus 6% with placebo.
• Up to 50% of tirzepatide participants achieved disease resolution, defined as AHI falling below 5 events per hour.
• These reductions represent the most dramatic improvement ever observed in a pharmaceutical sleep apnea trial.
• Tirzepatide participants also showed significant improvements in oxygen saturation, patient-reported sleep quality, and daytime sleepiness scores.

The First-Ever FDA-Approved Medication for OSA

Prior to December 2024, no drug had ever received FDA approval specifically for the treatment of obstructive sleep apnea. Treatment options were limited to CPAP and BiPAP machines, positional therapy, oral appliances, and surgery. The FDA approval of Zepbound for OSA represents a completely new therapeutic category — and validates the GLP-1 class as having meaningful clinical effects far beyond weight loss and diabetes management.

The labeled indication is specifically for moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30). The drug is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity — consistent with its existing obesity indication.

Who Qualifies for Zepbound for Sleep Apnea

• Adults with a BMI of 30 or greater (obese range).
• Diagnosed moderate-to-severe OSA, confirmed by polysomnography or a home sleep study showing AHI ≥15 events per hour.
• The medication is approved as an adjunct to existing OSA management — it is not required that patients already be on CPAP, but CPAP is not contraindicated.
• Patients who cannot tolerate CPAP, use it inconsistently, or want additional treatment on top of CPAP are all potential candidates.
• Patients without obesity (BMI <30) are NOT included in the approved indication, as the mechanism depends primarily on weight loss.

How GLP-1 Medications Improve Sleep Apnea: The Mechanism

The primary mechanism through which tirzepatide improves OSA is weight loss. In patients with obesity, excess adipose tissue — particularly fat deposits around the neck, throat, and upper airway — causes the airway to collapse during sleep. When this fat is reduced through significant weight loss, the airway becomes less prone to obstruction. SURMOUNT-OSA participants lost a mean of approximately 18% of body weight on tirzepatide, which directly reduces the anatomical obstruction responsible for most OSA events in people with obesity.

There is also emerging evidence of potential direct effects on upper airway muscle tone through GLP-1 receptors found in the brainstem and upper airway musculature. These receptors may influence the neuromuscular control of the pharyngeal muscles that keep the airway open during sleep. Whether this constitutes a meaningful additional mechanism beyond weight loss is still being investigated, but it may help explain why improvements in AHI sometimes exceeded what would be predicted from weight loss alone.

What About Semaglutide and Sleep Apnea?

Semaglutide (Wegovy, Ozempic) does not currently have an FDA approval specifically for obstructive sleep apnea. However, clinical evidence consistently shows that semaglutide-driven weight loss reduces OSA severity. In the SELECT cardiovascular outcomes trial, patients on semaglutide showed improvements in sleep-disordered breathing as a secondary outcome. Dedicated sleep apnea trials with semaglutide are ongoing.

In practice, patients on semaglutide who have OSA frequently report improvements in sleep quality and reductions in CPAP-required pressures as they lose weight. While semaglutide lacks the specific OSA label that tirzepatide now carries, the underlying biology is similar — weight reduction reducing upper airway obstruction.

Sleep apnea has long been the overlooked comorbidity of obesity. Patients with untreated OSA face elevated risks of hypertension, atrial fibrillation, stroke, cognitive decline, and motor vehicle accidents. A medication that simultaneously treats obesity and OSA through the same mechanism is a genuinely powerful clinical tool.

Practical Implications for Patients Who Struggle With CPAP

CPAP is highly effective when used correctly and consistently — but studies show that roughly 30–50% of patients are non-adherent. Some cannot tolerate the mask, others find the device disruptive to sleep or relationships, and many simply do not maintain the required nightly use. For these patients, Zepbound now offers a meaningful alternative pathway.

• Patients who cannot tolerate CPAP may now be offered Zepbound as a primary pharmacological approach to reduce AHI.
• Patients who use CPAP inconsistently may use Zepbound as an adjunct to further reduce OSA severity and potentially reduce CPAP pressure requirements.
• Patients who meet obesity criteria and want to address both excess weight and OSA with a single treatment can discuss Zepbound with their provider.
• As weight normalizes on tirzepatide, CPAP pressure settings often need to be adjusted downward — this requires follow-up sleep studies or auto-titrating CPAP devices.

Monitoring and Follow-Up

Patients starting Zepbound for OSA should maintain follow-up with both their prescribing provider and their sleep medicine team. As weight decreases, the degree of upper airway obstruction typically improves, which can change CPAP pressure needs. Using the same CPAP settings after losing 15–20% of body weight may result in over-treatment (CPAP pressure too high for the remaining degree of obstruction), which can itself disrupt sleep.

The Broader Significance

The FDA approval of Zepbound for OSA is significant not just for sleep medicine but for how we understand GLP-1 medications as a class. These drugs are no longer simply weight loss or diabetes medications. They are becoming the foundation of metabolic disease management across a wide range of conditions — each approval reinforcing their position as among the most clinically impactful drug class in modern medicine.

For patients with obesity-related OSA who have struggled with CPAP, who want additional treatment support, or who simply want to address the root cause of their airway obstruction, Zepbound now offers the first pharmacological option with FDA-backed evidence. This is a genuine advance in care.

Sources

• Malhotra et al. (2024). Tirzepatide for Moderate-to-Severe Obstructive Sleep Apnea. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.